T
Tarveda Therapeutics
Developing Pentarin miniature drug conjugate medicines to make a difference in the treatment of patients with solid tumor malignancies
About Tarveda Therapeutics
Tarveda Therapeutics is a biopharmaceutical company focused on developing Pentarin miniature drug conjugates to treat patients with solid tumor malignancies. These innovative medicines are designed to rapidly penetrate solid tumors, selectively bind to tumor targets, and accumulate anti-cancer payloads, enhancing the efficacy of cancer treatment. Tarveda operates in the oncology market and serves healthcare providers and patients battling solid tumors. The company generates revenue through licensing agreements, such as the one with SciClone Pharmaceuticals for PEN 866 in Greater China, and through the development and commercialization of its drug candidates. Tarveda's business model is centered on advancing its clinical programs and forming strategic partnerships to bring its therapies to market.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VCOther financing | Oct 2021 | $6M | $150M | Versant Ventures | — |
| SERIES DOther financing | Feb 2017 | $30M | $120M | Novo Holdings · Flagship Pioneering · +ND Capital · NEA | — |
Growth signals
Latest recorded traffic for Tarveda Therapeutics is 1.6K monthly website visits, up 492.6% over the last three months. Tarveda Therapeutics's team declined 16.7% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Tarveda Therapeutics in the Watertown ecosystem
The Tarveda Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
NEA
+ND Capital
Flagship Pioneering
Series B and later3 investors entered at this stage
Novo Seeds
Novo Holdings
Versant Ventures
Other known investors1 additional known investor
Massachusetts Institute of Technology
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Tarveda Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Tarveda Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.








